12:00 AM
Nov 12, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

AR-13324: Phase IIa data

Top-line data from a double-blind, U.S. Phase IIa trial in 80 patients with primary open-angle glaucoma or ocular hypertension showed that once-daily 0.01%, 0.02% and 0.04% AR-13324 given in the morning each met...

Read the full 143 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >